Related Experiment Videos
Cabergoline in severe ectopic or occult Cushing's syndrome
Mirela Diana Ilie1,2, Véronique Raverot3, François Tronc2,4
1Endocrinology Department, 'Groupement Hospitalier Est' Hospices Civils de Lyon, Lyon, France.
European Journal of Endocrinology
|May 4, 2019
Summary
Cabergoline shows promise for treating ectopic Cushing's syndrome. This drug combination helped manage hypercortisolism, allowing for reduced steroidogenesis inhibitor use in some patients.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Cabergoline demonstrates efficacy in moderate Cushing's disease.
- Effectiveness in ectopic or occult Cushing's syndrome requires further investigation.
Purpose of the Study:
- To evaluate cabergoline's role in managing severe ectopic or occult Cushing's syndrome.
- To assess the combination therapy of cabergoline with steroidogenesis inhibitors.
Main Methods:
- A case series of nine patients with severe ectopic or occult Cushing's syndrome.
- Combination therapy involving cabergoline and steroidogenesis inhibitors.
Main Results:
- Cabergoline facilitated rapid withdrawal of steroidogenesis inhibitors in three patients.
- Long-term hypercortisolism control was achieved in three cases.
- Literature review of 11 cases showed 10 responses to dopamine receptor agonists.
Conclusions:
- Limited experience suggests cabergoline's potential therapeutic value.
- Cabergoline may be a valuable option for treating ectopic or occult Cushing's syndrome.